Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REC-617 |
| Synonyms | |
| Therapy Description |
REC-617 (GTAEXS617) inhibits CDK7, potentially resulting in cell cycle arrest, increased apoptosis, and reduced proliferation of tumor cells, and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 3930, (Cancer Res (2025) 85 (8_Supplement_1): 366)). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REC-617 | REC 617REC617GTAEXS 617|GTAEXS-617|GTAEXS617 | CDK7 Inhibitor 16 | REC-617 (GTAEXS617) inhibits CDK7, potentially resulting in cell cycle arrest, increased apoptosis, and reduced proliferation of tumor cells, and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 3930, (Cancer Res (2025) 85 (8_Supplement_1): 366)). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RB1 del | Her2-receptor negative breast cancer | predicted - sensitive | REC-617 | Preclinical - Cell culture | Actionable | In a preclinical study, REC-617 (GTAEXS617) induced cell cycle arrest and apoptosis in CDK4/6 inhibitor-resistant, ESR1-positive, ERBB2 (HER2)-negative breast cancer cells with Rb deletion (Cancer Res (2025) 85 (8_Supplement_1): 366). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07633756 | Phase I | REC-617 | A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy | Not yet recruiting | USA | 0 |
| NCT05985655 | Phase Ib/II | REC-617 Capecitabine + REC-617 Pegylated liposomal doxorubicin + REC-617 Fulvestrant + REC-617 Bevacizumab + Paclitaxel + REC-617 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (ELUCIDATE) | Recruiting | USA | GBR | BEL | 0 |
CKB BOOST